AVN 63.71 Increased By ▲ 0.02 (0.03%)
BOP 8.77 Decreased By ▼ -0.01 (-0.11%)
CHCC 134.55 Increased By ▲ 0.05 (0.04%)
DCL 10.01 Decreased By ▼ -0.04 (-0.4%)
DGKC 108.01 Increased By ▲ 0.01 (0.01%)
EFERT 64.27 Decreased By ▼ -0.18 (-0.28%)
EPCL 41.21 Decreased By ▼ -0.09 (-0.22%)
FCCL 21.00 No Change ▼ 0.00 (0%)
FFL 15.10 Increased By ▲ 0.05 (0.33%)
HASCOL 15.05 Decreased By ▼ -0.03 (-0.2%)
HBL 130.50 Decreased By ▼ -0.60 (-0.46%)
HUBC 81.75 Increased By ▲ 0.13 (0.16%)
HUMNL 7.35 Decreased By ▼ -0.05 (-0.68%)
JSCL 24.29 No Change ▼ 0.00 (0%)
KAPCO 28.49 Increased By ▲ 0.14 (0.49%)
KEL 3.70 Decreased By ▼ -0.01 (-0.27%)
LOTCHEM 11.72 Decreased By ▼ -0.03 (-0.26%)
MLCF 41.98 Increased By ▲ 0.13 (0.31%)
OGDC 93.20 Decreased By ▼ -0.13 (-0.14%)
PAEL 32.90 Decreased By ▼ -0.02 (-0.06%)
PIBTL 12.76 Decreased By ▼ -0.10 (-0.78%)
PIOC 95.00 No Change ▼ 0.00 (0%)
POWER 9.75 Decreased By ▼ -0.02 (-0.2%)
PPL 83.50 Decreased By ▼ -0.10 (-0.12%)
PSO 200.02 Increased By ▲ 0.02 (0.01%)
SNGP 56.52 Decreased By ▼ -0.08 (-0.14%)
STPL 13.15 No Change ▼ 0.00 (0%)
TRG 46.90 Increased By ▲ 0.30 (0.64%)
UNITY 23.05 Increased By ▲ 0.05 (0.22%)
WTL 1.04 Decreased By ▼ -0.01 (-0.95%)
BR100 4,133 Decreased By ▼ -155.2 (-3.62%)
BR30 21,019 Decreased By ▼ -858.48 (-3.92%)
KSE100 39,888 Decreased By ▼ -1298.86 (-3.15%)
KSE30 16,750 Decreased By ▼ -546.72 (-3.16%)
COVID-19 TOTAL DAILY

BEIJING: A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.

Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month.

Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end. And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public "around November or December."

Wu Guizhen did not specify which vaccine she was referring to, but said "based on the phase 3 clinical results, the current progress is very smooth."

Wu added that she had taken a vaccine in April and has felt good over the past few months, although she did not specify which candidate she had taken. There are currently nine vaccine candidates in late-stage human trials, although some have hit recent obstacles - pharma giant AstraZeneca and Oxford University momentarily paused clinical trials last week after a volunteer developed an unexplained illness.

Some of China's vaccine candidates have already been offered to essential workers under an emergency use programme. A Sinovac spokesman told AFP this month that "tens of thousands" of people had voluntarily taken its vaccine, including 90 percent of its employees and their families - between 2,000 and 3,000 people. In June, China's military approved a vaccine for use within its ranks developed by its research unit and a biotech firm.